Oncology

Cancer research
#Cancer #Cancer research #Cell therapy #Clinical trials #Oncology

The personal touch: the scientist making an impact in cancer research

Listen to this article on the DDW Podcast: At 33, Martyn Hiscox is an inspiration to scientists in oncology research. Principal scientist with Adaptimmune, a UK cell therapy biotech, Lu Rahman uncovers Hiscox’s passion, dedication and the personal reason for developing cell therapy treatments for cancer. Hiscox clearly has immense respect… Read More

#Cancer Research #Editor's Choice #Exclusive Content #News

#Clinical trials #Drug development #Drug discovery #Infectious diseases #mRNA #Novel therapeutics #Oncology #Research

This week in drug discovery (2-6 August)

News round-up by DDW’s Megan Thomas for 2-6 August This week has seen results released, research continued, and clinical trial phases completed. DDW’s Megan Thomas has rounded up her top five stories showing promise in the drug discovery industry. Cardiac patients receiving nasal gel showed reduction of S. aureus… Read More

#News #Trending News

#Cancer research #Oncology #Pharmaceuticals

Appointment strengthens the experience of RareCan

RareCan, a new company accelerating research into rare cancers, has appointed Dr Anita Cooper as Non-Executive Director. The appointment is said to strengthen the scientific and pharmaceutical experience of RareCan’s board in support of the company’s planned commercial growth. With over 30 years’ global business experience, Cooper has worked across… Read More

#Business & Investment #Cancer Research #News

#Biotherapeutics #Cancer immunotherapy #Cancer research #Chemotherapy #Oncology #Therapeutics

Study could combat aggressive chemotherapy resistant TNBC

A Mount Sinai study titled Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease describes how a novel therapeutic (108600) combats aggressive chemotherapy-resistant triple-negative breast cancer (TBNC). 108600 targets and inhibits breast cancer stem cells, a subpopulation of cells found within patient triple negative… Read More

#Editor's Choice #News

#Aptamers #CAR-T #Immunotherapy #Oncology

Research collaboration will develop bispecific agents for oncology

Ixaka and SomaLogic have created a research collaboration to support the development of aptamer-based bispecific therapeutics. The collaboration will evaluate the safety and efficacy of antigen-specific SOMAmer reagents (modified aptamers that bind tightly and specifically to protein targets) previously identified and screened by SomaLogic as potential candidates for combination with… Read More

#Cancer Research #News

#Cancer research #Drug development #Drug discovery #Drug innovation #Oncology #Research #Therapeutics

Sitting down with… Mari Scheiffele, Novartis

Mari Scheiffele is the General Manager for Oncology in the UK & Ireland at Novartis, responsible for launching innovative oncology therapies that can help to change the lives of people living with different types of cancer. She speaks to Lu Rahman about her passion for working with her teams to… Read More

#Cancer Research #Editor's Choice #Exclusive Content #News #Opinion

#Cancer research #Cell / tissue culture #Immunology #Oncology

Internal communication find that may regulate tissue repair

National Institutes of Health scientists and their collaborators have identified an internal communication network in mammals that may regulate tissue repair and inflammation, providing new insights on how diseases such as obesity and inflammatory skin disorders develop. The new research is published in Cell. The billions of organisms living on… Read More

#News

#HIV #Immunology #Infectious diseases #Oncology #Pharmaceuticals

New GSK to deliver step-change in growth and performance

GlaxoSmithKline has announced New GSK, which will deliver step-change in growth and performance over next ten years, driven by a high-quality Vaccines and Specialty Medicines portfolio and late-stage pipeline. New GSK will keep a 20% stake in the consumer healthcare business. The Independent confirmed: “The unit will be listed on… Read More

#News

#Cancer research #Clinical trials #Immunotherapy #Oncology #Pharmaceuticals

Unlocking the potential for autologous vaccines

In the last decade, cancer immunotherapy has emerged as one the most promising treatments for the disease. In a recent pilot study, Professor Joachim Drevs and his co-authors; Joachim Ahlers, Eglys Gonzalez Marcano and Leona Kröhle describe how a new autologous vaccine developed in partnership with cancer clinic RGCC created… Read More

#Cancer Research #Editor's Choice #Exclusive Content #News #Opinion

#Biotherapeutics #Cancer research #Drug delivery #Drug discovery #Oncology

New oncology research and development collaboration

Genmab and Bolt Biotherapeutics have entered into an oncology research and development collaboration. Together, the companies will evaluate Genmab antibodies and bispecific antibody engineering technologies in combination with Bolt’s proprietary Boltbody immune-stimulating antibody conjugate (ISAC) technology platform, with the goal of discovering and developing next-generation, immune-stimulatory, antibody-based conjugate therapeutics for… Read More

#News

#Antibodies #Awards #Biologics / Biotechnology #Drug development #Oncology #Therapeutics

Matwin spotlights innovation in the fight against cancer

Matwin has picked four companies that will now receive investment from the French oncology accelerator. This was during the MEET2WIN European Oncology Partnering Convention. Step Pharma was awarded ‘First-in-class therapeutic innovation’. The startup’s lead program (STP938) is based on a novel class of oral nucleotide synthesis inhibitors that target CTPS1… Read More

#News

#Cancer research #Drug targets #Immuno-oncology #Oncology #Research #Vaccines

Personalised cancer vaccine 45% effective at targeting tumours

Researchers have developed an effective vaccine that re-engineers cells from a patient’s tumour to target and destroy cancer cells. The results, published in the peer-reviewed Journal of Clinical Oncology, show that 45% of patients treated with an autologous cell vaccine, created from their own cancer cells, had a confirmed anti-tumour… Read More

#News

#Cancer #Clinical trial #Life sciences #Novel therapeutics #Oncology

SignalChem collaborates with Merck on advanced non-small cell lung cancer

SignalChem Lifesciences, a clinical-stage company who develop novel targeted therapies for oncology, has announced its collaboration with Merck, through a subsidiary, to evaluate the combination of SLC-391, a selective AXL inhibitor developed by SignalChem, with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with advanced non-small cell lung cancer (NSCLC). AXL,… Read More

#Cancer Research #News

#Biopharmaceuticals #Drug development #Drug discovery #Oncology

LDC and Cumulus Oncology announce collaboration

The Lead Discovery Centre (LDC) and Cumulus Oncology are collaborating to enable the two organisations to accelerate the discovery and development of novel oncology therapies. LDC contributes drug discovery expertise and a team of scientists with the ability to develop assets modulating a range of oncology targets derived from its… Read More

#News

#Cancer research #Drug development #Institute of Cancer Research #Oncology #Therapeutics

Resistance-busting ICR drug enters clinical trial

The Institute of Cancer Research (ICR), London, has discovered a drug that could counteract drug resistance in patients with cancers including acute myeloid leukaemia. It has entered a Phase I clinical trial at The Royal Marsden NHS Foundation Trust. The drug, now called EP0042, is a dual inhibitor of cancer-driving… Read More

#Cancer Research #Editor's Choice #News